GenMont Biotech Incorporation (3164.TW)
TWD 19.95
(-0.5%)
TWD 19.95
(-0.5%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 34.59 Million | 137.94 Million | 111.65 Million | 118.27 Million | 74.51 Million | 56.03 Million |
| Net Income | 32.99 Million | 66.25 Million | 139.42 Million | 76.84 Million | 75.54 Million | 184.65 Million |
| Depreciation & Amortization | 64.78 Million | 50.41 Million | 21.13 Million | 20.87 Million | 21.23 Million | 27.06 Million |
| Deferred income taxes | - | - | - | -11.78 Million | 9.94 Million | -120.2 Million |
| Stock-based compensation | - | - | - | 23 Thousand | 345 Thousand | 1.37 Million |
| Change in working capital | -19.85 Million | 47.67 Million | -19.03 Million | 32.36 Million | -28.32 Million | -34.09 Million |
| Other non-cash items | -43.32 Million | -26.4 Million | -29.86 Million | -58 Thousand | -4.22 Million | -2.75 Million |
| Investing Cash Flow | -75.37 Million | -83.7 Million | -153.07 Million | 6.77 Million | 4.41 Million | -1.42 Million |
| Investments in PPE | -35.54 Million | -70.93 Million | -117.11 Million | -138.98 Million | -393.71 Million | -275.29 Million |
| Acquisitions | 283 Thousand | 5.79 Million | 3.53 Million | 86.42 Million | 33.84 Million | 787.62 Million |
| Investment purchases | -406.43 Million | -300.55 Million | -61.49 Million | 144.52 Million | -33.84 Million | -701.6 Million |
| Sales/Maturities of investments | 365.37 Million | 286.93 Million | -175 Thousand | 144.52 Million | 366.8 Million | 201.68 Million |
| Other Investing Activities | 939 Thousand | -4.95 Million | 22.17 Million | -229.7 Million | 31.33 Million | -13.84 Million |
| Financing Cash Flow | -36.81 Million | -91.08 Million | -61.36 Million | -49.33 Million | -100.93 Million | 2.29 Million |
| Debt repayment | -22.69 Million | -1.43 Million | -1.59 Million | -1.96 Million | -1.89 Million | -1.13 Million |
| Dividends payments | -60.46 Million | -95 Million | -49.21 Million | -70.25 Million | -133.36 Million | - |
| Common Stock Repurchased | 45.39 Million | - | - | -62.4 Million | - | - |
| Common Stock Issuance | 2.81 Million | - | 669 Thousand | -889 Thousand | 520 Thousand | - |
| Other Financing Activities | -1.86 Million | 5.35 Million | 669 Thousand | 86.18 Million | 34.33 Million | 2.29 Million |
| Accounts receivables | 11.58 Million | 6.09 Million | -15.45 Million | 29.76 Million | 3.97 Million | -6.74 Million |
| Accounts payables | -6.51 Million | 2.97 Million | 4 Million | -317 Thousand | 203 Thousand | -16.27 Million |
| Inventory | -31.66 Million | -18.21 Million | 1.06 Million | -4.47 Million | 9.32 Million | 25.69 Million |
| Other working capital | 6.74 Million | 56.82 Million | -8.64 Million | 7.4 Million | -41.82 Million | -59.79 Million |
| Cash at beginning of period | 133.68 Million | 169.95 Million | 274.84 Million | 191.67 Million | 225.29 Million | 170.17 Million |
| Cash at end of period | 55.59 Million | 133.68 Million | 169.95 Million | 274.84 Million | 191.67 Million | 225.29 Million |
| Capital Expenditure | -35.54 Million | -70.93 Million | -117.11 Million | -138.98 Million | -393.71 Million | -275.29 Million |
| Effect of forex changes on cash | -500 Thousand | 575 Thousand | -2.11 Million | 7.45 Million | -11.62 Million | -1.78 Million |
| Net cash flow / Change in cash | -78.09 Million | -36.26 Million | -104.89 Million | 83.17 Million | -33.62 Million | 55.11 Million |
| Free Cash Flow | -941 Thousand | 67.01 Million | -5.45 Million | -20.71 Million | -319.2 Million | -219.26 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 14.67 Million | 34.74 Million | 32.99 Million | -2.01 Million | 25.46 Million | 908 Thousand |
| Depreciation & Amortization | 18.09 Million | 17.76 Million | 64.78 Million | 17.52 Million | 16.61 Million | 15.22 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -9.72 Million | -7.41 Million | -19.85 Million | 1.21 Million | 5.31 Million | -10.19 Million |
| Other non-cash items | 12.53 Million | 32.01 Million | -43.32 Million | 11.36 Million | -29.11 Million | -25.2 Million |
| Investing Cash Flow | 23.77 Million | -48.19 Million | -75.37 Million | -38.62 Million | -60.52 Million | 89.71 Million |
| Investments in PPE | -228 Thousand | -31.24 Million | -35.54 Million | -116 Thousand | -24.62 Million | -6.87 Million |
| Acquisitions | - | - | 283 Thousand | - | -1.94 Million | - |
| Investment purchases | -224.52 Million | -111.54 Million | -406.43 Million | -44.67 Million | -210.53 Million | -91.49 Million |
| Sales/Maturities of investments | 248.09 Million | 93.93 Million | 365.37 Million | 5.23 Million | 174.33 Million | 185.81 Million |
| Other Investing Activities | 624 Thousand | 667 Thousand | 939 Thousand | 933 Thousand | 2.25 Million | 2.27 Million |
| Financing Cash Flow | 8.53 Million | 40.16 Million | -36.81 Million | -531 Thousand | -35.4 Million | -440 Thousand |
| Debt repayment | -9.18 Million | -40.86 Million | -22.69 Million | -6000.00 | -22.69 Million | -440 Thousand |
| Dividends payments | - | - | -60.46 Million | - | -60.46 Million | - |
| Common Stock Repurchased | - | - | 45.39 Million | - | 45.38 Million | - |
| Common Stock Issuance | - | - | 2.81 Million | - | 2.81 Million | - |
| Other Financing Activities | -654 Thousand | -50 Thousand | -1.86 Million | -525 Thousand | -451 Thousand | -440 Thousand |
| Accounts receivables | 1.42 Million | 5.32 Million | 11.58 Million | 8.46 Million | 3.23 Million | -3.16 Million |
| Accounts payables | -2.74 Million | 1.71 Million | -6.51 Million | 3.64 Million | -4.68 Million | 828 Thousand |
| Inventory | 1.3 Million | -3.34 Million | -31.66 Million | -12.5 Million | -8.44 Million | -2.98 Million |
| Other working capital | -9.7 Million | -11.11 Million | 6.74 Million | 1.6 Million | 15.21 Million | -4.87 Million |
| Cash at beginning of period | 93.25 Million | 55.59 Million | 133.68 Million | 67.58 Million | 142.79 Million | 75.13 Million |
| Cash at end of period | 191.78 Million | 93.25 Million | 55.59 Million | 55.59 Million | 67.58 Million | 142.79 Million |
| Capital Expenditure | -228 Thousand | -31.24 Million | -35.54 Million | -116 Thousand | -24.62 Million | -6.87 Million |
| Effect of forex changes on cash | 177 Thousand | 415 Thousand | -500 Thousand | -931 Thousand | 2.44 Million | -2.34 Million |
| Net cash flow / Change in cash | 98.52 Million | 37.65 Million | -78.09 Million | -11.98 Million | -75.2 Million | 67.65 Million |
| Free Cash Flow | -864 Thousand | 14.02 Million | -941 Thousand | 27.97 Million | -6.34 Million | -26.14 Million |
688105
CHKEL
7939
ACLS
2340
EPAC